Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer

The clinical steroidal selective estrogen receptor (ER) degrader (SERD), fUlvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bioavailable, nonsteroidal SERDs, currently in clinical trials. These trials address local breast...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Med Chem
Auteurs principaux: Lu, Yunlong, Gutgesell, Lauren M., Xiong, Rui, Zhao, Jiong, Li, Yangfeng, Rosales, Carlo I., Hollas, Michael, Shen, Zhengnan, Gordon-Blake, Jesse, Dye, Katherine, Wang, Yueting, Lee, Sue, Chen, Hu, He, Donghong, Dubrovyskyii, Oleksii, Zhao, Huiping, Huang, Fei, Lasek, Amy W., Tonetti, Debra A., Thatcher, Gregory R. J.
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7261373/
https://ncbi.nlm.nih.gov/pubmed/31746603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.9b01580
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires